Tofogliflozin

Tofogliflozin is a medication used in the treatment of Type 2 diabetes. It belongs to the class of drugs known as SGLT2 inhibitors, which work by preventing the kidneys from reabsorbing glucose back into the blood, thereby promoting the excretion of glucose through urine.

Mechanism of Action

Tofogliflozin works by inhibiting the SGLT2 protein in the kidneys. This protein is responsible for approximately 90% of the reabsorption of glucose from the glomerular filtrate back into the blood. By inhibiting this protein, tofogliflozin causes an increase in the excretion of glucose through the urine, thereby reducing blood glucose levels.

Uses

Tofogliflozin is used in the treatment of Type 2 diabetes. It is often used in combination with other antidiabetic medications such as Metformin or Insulin when diet and exercise alone do not provide adequate control of blood glucose levels.

Side Effects

Common side effects of tofogliflozin include urinary tract infections, increased urination, and genital yeast infections. Less common but more serious side effects can include dehydration, kidney problems, and diabetic ketoacidosis.

Contraindications

Tofogliflozin is contraindicated in patients with severe renal impairment, end-stage renal disease, or dialysis. It is also contraindicated in patients with a history of hypersensitivity to tofogliflozin or any of its components.

See Also

• Sodium-glucose cotransporter 2 inhibitors
• Type 2 diabetes
• Metformin
• Insulin

Tofogliflozin Resources
Most recent articles Ongoing trials	Wikipedia

• 

  Tofogliflozin monohydrate skeletal 3D structure

• 

  Tofogliflozin skeletal 3D structure